Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, launches today its 6th call for proposals with the aim of establishing collaborations in dermatological research to find innovative therapies for skin diseases. The call is launched through AlmirallShare, the company’s R&D open innovation platform, and looks for partnering opportunities for new assets in order to offer breakthrough innovation and accelerate the generation of new treatments for skin conditions. Each call aims to respond to a specific challenge.
Assets submitted for consideration should involve any therapeutic modality, such as small molecules, biologics or advanced therapies, in research or preclinical development stages, and target immuno-inflammatory pathways or be suitable for dermato-oncological or rare dermatological indications.
Innovative therapies for skin diseases
Maximising the value of your assets for patients suffering from a dermatological conditionRead More
The submitted proposals may be eligible for an advanced research or preclinical development collaboration with Almirall, research grants, and further asset characterisation on key dermatological assays by Almirall. They may also have the potential to establish a long-term business partnership with the company.
AlmirallShare is an open innovation platform which aims to empower scientists to improve skin health by fostering collaborative projects with partners worldwide. Since its launch in 2017, more than 1,000 scientists have shown interest in participating and 410 proposals have been received. To date, eight collaborations have been established, based on new therapies (IDIBAPS, University of Turin, University of South Australia, Hospital de la Santa Creu i Sant Pau), new targets (Dublin City University, University of Namur), and new preclinical models (University College Dublin, University of Sheffield).
“AlmirallShare has increasingly earned recognition from the scientific community since the first call was launched in 2017. We truly believe in groundbreaking innovation and cross collaboration as the way to succeed, and AlmirallShare allows us to strengthen our network to identify new opportunities in Medical Dermatology” says Maribel Crespo, Almirall’s Research Alliances and AlmirallShare Leader.
The initiative allows the company to extend its academic collaboration network, develop a deep understanding of disease drivers and patient needs, and access innovation. AlmirallShare platform combines the science and creativity of experts from around the world with the company’s knowledge and expertise.
Scientists affiliated with start-ups, biotechs, universities, research centres, and pharmaceutical companies from anywhere in the world may submit their proposals on sharedinnovation.almirall.com until October 31st, 2021.